Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Chief Medical Officer | May 23, 2023 | May 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RELMADA THERAPEUTICS, INC.
Report date May 23, 2023 · Filed May 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,121 |
Reported balance
After 2023-05-23 transaction · row 1
1 source rowRow 1 · 2023-05-23 · Purchase · Acquired 10,000 · Balance 10,121 F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2: Purchase prices range from $3.135 to $3.2096 per share, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2: Purchase prices range from $3.135 to $3.2096 per share, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2023 Filed May 24, 2023 13:00 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 10,000 | $3.18 | $31,800.00 |
DisclosureSEC source: 0001213900-23-042554 · ownership.xml · nonDerivative · entry 1 O'Gorman Cedric · CIK 0001962179 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,121 F1 · shares: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2 · price: Purchase prices range from $3.135 to $3.2096 per share, inclusive. Read SEC document |
| January 06, 2023 Filed Jan 13, 2023 22:54 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $3.29 | $0.00 |
DisclosureSEC source: 0001213900-23-002871 · ownership.xml · derivative · entry 1 O'Gorman Cedric · CIK 0001962179 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common stock · 400,000 shares Expires 2033-01-06 F1 · derivative.exercise_date: The shares vest in 16 equal quarterly installments commencing on April 6, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.